Ophthalmic pharmaceutical composition, preparation methods and uses of the same

1 . An ophthalmic pharmaceutical composition in the form of an oil-in-water (O/W) emulsion comprising:

a) an organic polyol compound;

b) a fragmented polymer, wherein the fragmented polymer comprises monomers;

c) at least one synthetic phospholipid of a phosphatidylcholine type; and

d) at least one pharmaceutically acceptable excipient.

2 . The composition according to claim 1 , wherein the organic polyol compound is selected from the group consisting of propylene glycol, polyethylene glycol 300 and sorbitol.

3 . The composition according to claim 1 , wherein the fragmented polymer is selected from the group consisting of guar gum, gellan gum, hydroxypropylmethylcellulose, sodium hyaluronate, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone and polyvinyl alcohol.

4 . The composition according to claim 1 , further comprising castor oil and the phospholipid is selected from the group consisting of DPPC (1,2-dipalmitol-sn-glycero-3-phosphocholine), DSPC (1,2-distearol-sn-glycero-3-phosphocholine, DOPC (1,2-Dioleol-sn-glycero-3-phosphocholine), DEPC (1,2-dierucil-sn-glycero-3-phosphocholine), and DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine).

5 . The composition according to claim 1 , wherein the pharmaceutically acceptable excipients are selected from the group consisting of surfactants, boric acid, sodium borate decahydrate, disodium edetate dihydrate, glycerin, and mixtures thereof.

6 . The composition according to claim 1 , wherein the organic polyol compound is propylene glycol.

7 . The composition according to claim 1 , wherein the fragmented polymer is sodium hyaluronate.

8 . The composition according to claim 1 , wherein the phospholipid is 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC).

9 . The composition according to claim 4 , wherein:

the propylene glycol is in a ratio between 0.1 to 0.6% w/v;

the fragmented polymer is in a proportion of 0.1 to 0.5% w/v;

the phospholipid is DMPC in a proportion between 0.001 to 0.01% w/v; and

the castor oil is in a proportion of between 1.0 to 5.0% w/v.

10 . The composition according to claim 7 , wherein the sodium hyaluronate is fragmented in the form of monomers dispersed in the composition.

11 . The composition according to claim 1 , wherein the phospholipid forms micelles and the particle size distribution in the micelles is between 30 to 260 nm, optionally between 32 to 255 nm or between 82.5 to 92.5 nm.

12 . The composition of claim 1 , wherein the composition is adapted to: maintain the diameter of a soft contact lens within about 1.5 to about 2% of the initial diameter of the soft contact lens; maintain the thickness of the soft contact lens within 10% of the initial thickness of the soft contact lens; maintain the UV light transmittance value of the soft contact lens within about +/−5.0% of the initial UV light transmittance values of the soft contact lens; and maintain the diopters of the soft contact lens within about +/−25% of the initial diopters of the soft contact lens.

13 . A method for the manufacture of the ophthalmic pharmaceutical composition of claim 1 , the method comprising:

(a) adding water to a tank at a temperature from about 20 to about 30° C.;

(b) adding to (a): 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), boric acid, sodium borate decahydrate, disodium edetate dihydrate, glycerin, propylene glycol, sodium hyaluronate and castor oil and further adding at least one surfactant to produce an oily-aqueous preparation, wherein the water constitutes about 60% to about 65% of the volume of the composition and the water is agitated during the step of adding (b);

(c) emulsifying the oily-aqueous preparation of (b) to produce an emulsion;

(d) sterilizing the emulsion of (c) by filtration to produce a sterilized filtered emulsion; and

(e) homogenizing and emulsifying the sterilized filtered emulsion of (d) to produce the ophthalmic pharmaceutical composition.

14 . The method of claim 13 , wherein the tank of (a) is a stainless-steel tank and/or the water of (a) is injectable grade water.

15 . The method of claim 13 , wherein the agitation of the water in (b) is constant, and/or the emulsifying of (c) is a mechanical emulsification process, optionally the agitation is in a range of 78 rpm to about 840 rpm.

16 . The method of claim 13 , wherein: the filtration of (d) comprises filtering through sterilizing membranes, optionally wherein the sterilizing membranes have a pore size of about 0.2 μm, the homogenizing of (e) comprises about a 60-minute homogenization process, and/or the emulsifying of (e) comprises a three-cycle mechanical emulsification process in a pressure range of about 10,000 psi to about 30,000 psi.

17 . A container comprising the ophthalmic pharmaceutical composition according to claim 1 .

18 . A pharmaceutical system comprising:

(a) a low-density polyethylene container with an assembled high-density polyethylene closure-device, wherein the low-density polyethylene container comprises a system of silicone and low-density polyethylene valves;

(b) the ophthalmic pharmaceutical composition of claim 1 ; and

(c) a buffer solution based on borates in a proportion not greater than 0.1%.

19 . The pharmaceutical system according to claim 18 , wherein the system is adapted for the conservation and administration of the composition of claim 1 , at a pH of between 6.5 to 7.5 and an osmolality of 200 to 400 mOsmol/kg.

20 . A method for treating and/or relieving dry eye and/or non-bacterial conjunctivitis in a subject in need thereof, the method comprising administering the ophthalmic pharmaceutical composition of claim 1 to the subject.